Equashield is a leading global provider of closed system transfer devices (CSTDs) designed to protect healthcare professionals from exposure to hazardous drugs.
With a relentless focus on quality, safety, and ease of use, Equashield’s product offerings are based on proprietary technologies spanning both manual CSTDs and novel automated compounding solutions – including a next-generation automated compounding system utilising artificial intelligence to deliver superior performance.
Company Background
- Since its founding in 2009, Equashield has recorded robust growth fuelled by continued product innovation, high customer satisfaction, and the pioneering of new technological solutions for handling hazardous drugs.
- Products are sold across five continents Equashield is a leading CSTD provider in the largest global market, the US.
Vision & Outlook
- Opportunity to leverage its technological edge to further accelerate growth.
- Pipeline of innovative compounding technologies, including a novel automated drug compounding system.
- Vast potential of compounding automation to improve safety and efficiency in the handling of hazardous drugs.
SECTOR
Healthcare
REVENUES 2023
EUR 110 million
EMPLOYEES
460
OWNERSHIP
Fund XI
INVESTMENT DATE
2022
HEAD OFFICE
Tefen, Israel